PTK2 and ovarian cancer: However, treatment with 10 μM IMD-4482 did not alter the expression of either αV integrin or β3 integrin (Figure 4A), while the drug successfully inhibited the phosphorylation of FAK and ERK in a dose-dependent manner in PAI-1-positive ovarian cancer cells (SKOV3ip1 and HeyA8 cells) but not OVCAR3 cells (Figure 4B).